Drug Development

Gilead Sciences FDA Approval Clinical Trials Cell Therapy Gene Therapy Oncology

Frazier Life Sciences Closes $1.3 Billion Early-Stage Biotech Fund

The third major life-sciences fundraise in two months reflects investor consolidation into larger pools following a downturn in smaller biotech financing.

4 ARTICLES

2w ago

Lenacapavir Injection Shows 96% Efficacy in Preventing HIV

Drug Development

Frazier Life Sciences Closes $1.3 Billion Early-Stage Biotech Fund

FDA Flags Possible License Revocation for Sarepta’s Elevidys

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial

FDA Approves Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

Lenacapavir Injection Shows 96% Efficacy in Preventing HIV